UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency

Science translational medicine, 2022-02, Vol.14 (631), p.eabg8070

2022

Volltextzugriff (PDF)

Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry

Journal of immunological methods, 2021-05, Vol.492, p.112955-112955, Article 112955

2021

Volltextzugriff (PDF)

Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8 + T Cells within Polyomavirus-Driven Merkel Cell Carcinomas

Cancer immunology research, 2020-05, Vol.8 (5), p.648-659

2020

Volltextzugriff (PDF)

Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I

Cancer immunology research, 2014-01, Vol.2 (1), p.27-36

2014

Volltextzugriff (PDF)

Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I

Cancer immunology research, 2014, Vol.2 (1), p.27-36

2014

Volltextzugriff (PDF)

Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Blood advances, 2024-01, Vol.8 (2), p.453-467

2024

Volltextzugriff (PDF)

Addressing Relapsed Disease Following Cellular Therapy

Blood, 2020-11, Vol.136 (Supplement 1), p.SCI1-SCI1

Chapuis, Aude G.

2020

Volltextzugriff (PDF)

Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine

JCI insight, 2024-06, Vol.9 (14)

2024

Volltextzugriff (PDF)

MR1-restricted T cell clonotypes are associated with "resistance" to Mycobacterium tuberculosis infection

JCI insight, 2024-05, Vol.9 (9)

2024

Volltextzugriff (PDF)

Tracking the fate and origin of clinically relevant adoptively transferred CD8 + T cells in vivo

Science immunology, 2017-02, Vol.2 (8)

2017

Volltextzugriff (PDF)

HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo

Blood, 2011-05, Vol.117 (20), p.5391-5402

2011

Volltextzugriff (PDF)

T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies

Current hematologic malignancy reports, 2016-08, Vol.11 (4), p.311-317

2016

Volltextzugriff (PDF)

Abstract IA06: Optimizing T-cell receptor gene therapy for cancer

Cancer immunology research, 2020-03, Vol.8 (3_Supplement), p.IA06-IA06

Chapuis, Aude G.

2020

Volltextzugriff (PDF)

Leukemia Blasts Induce NK-like Dysfunction in AML-Specific T Cells

Blood, 2023-11, Vol.142 (Supplement 1), p.4849-4849

2023

Volltextzugriff (PDF)

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Blood, 2023-11, Vol.142 (Supplement 1), p.2137-2137

2023

Volltextzugriff (PDF)

Elevated Metabolite Secretion Facilitates a Treg-Mediated Immunosuppressive Microenvironment in the Solid Tumor

Blood, 2023-11, Vol.142 (Supplement 1), p.3458-3458

2023

Volltextzugriff (PDF)

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Blood, 2023-11, Vol.142 (Supplement 1), p.2126-2126

2023

Volltextzugriff (PDF)

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Blood, 2023-11, Vol.142 (Supplement 1), p.2131-2131

2023

Volltextzugriff (PDF)

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.3495-3495

2023

Volltextzugriff (PDF)

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood, 2023-11, Vol.142 (Supplement 1), p.6848-6848

2023

Volltextzugriff (PDF)

Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy

AIDS (London), 2000-09, Vol.14 (13), p.1887-1897

2000

Volltextzugriff (PDF)

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.7447-7449

2022

Volltextzugriff (PDF)

Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count

AIDS (London), 2000-10, Vol.14 (15), p.2257-2263

2000

Volltextzugriff (PDF)

26 – 50 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(92)

Sprache

Englisch
(92)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Humans
(35)
Life Sciences & Biomedicine
(34)
Male
(17)
Adult
(15)
Female
(15)
Middle Aged
(13)
Immunology
(11)
Aged
(10)
Hematology
(10)
Animals
(9)
Immunotherapy, Adoptive - Methods
(9)
Medicine, Research & Experimental
(9)
Research & Experimental Medicine
(9)
Immunotherapy
(8)
Mice
(7)
Receptors, Antigen, T-Cell - Genetics
(7)
T-Lymphocytes - Immunology
(7)
Lymphocytes
(6)
Oncology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency

Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry

Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8 + T Cells within Polyomavirus-Driven Merkel Cell Carcinomas

Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I

Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I

Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Addressing Relapsed Disease Following Cellular Therapy

Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine

MR1-restricted T cell clonotypes are associated with "resistance" to Mycobacterium tuberculosis infection

Tracking the fate and origin of clinically relevant adoptively transferred CD8 + T cells in vivo

HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo

T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies

Abstract IA06: Optimizing T-cell receptor gene therapy for cancer

Leukemia Blasts Induce NK-like Dysfunction in AML-Specific T Cells

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Elevated Metabolite Secretion Facilitates a Treg-Mediated Immunosuppressive Microenvironment in the Solid Tumor

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count

Suchergebnisse filtern